HC Wainwright reissued their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB – Free Report) in a research note released on Friday,Benzinga reports.
Separately, Jefferies Financial Group raised Assembly Biosciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $2.00 to $35.00 in a research report on Friday, September 20th.
Check Out Our Latest Report on Assembly Biosciences
Assembly Biosciences Price Performance
Insider Buying and Selling at Assembly Biosciences
In other Assembly Biosciences news, major shareholder Alexander Schornstein purchased 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The shares were acquired at an average price of $14.58 per share, for a total transaction of $145,800.00. Following the completion of the purchase, the insider now owns 703,113 shares in the company, valued at $10,251,387.54. The trade was a 1.44 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 394 shares of company stock valued at $5,894 over the last 90 days. 5.10% of the stock is owned by corporate insiders.
Institutional Trading of Assembly Biosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its holdings in Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 3,442 shares in the last quarter. FMR LLC lifted its position in shares of Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 3,635 shares during the last quarter. Armistice Capital LLC bought a new position in shares of Assembly Biosciences during the second quarter worth about $6,421,000. Renaissance Technologies LLC grew its stake in Assembly Biosciences by 39.2% in the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 15,451 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 7,690 shares during the last quarter. Institutional investors own 19.92% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Read More
- Five stocks we like better than Assembly Biosciences
- What Are Dividend Contenders? Investing in Dividend Contenders
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- 3 Monster Growth Stocks to Buy Now
- How AI Implementation Could Help MongoDB Roar Back in 2025
- What Are Trending Stocks? Trending Stocks Explained
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.